Like every April, the Czech immunological Society (CIS) in collaboration with the Institute of Microbiology of the Czech Academy of Sciences (IMIC) celebrated the International Day of Immunology. The celebration began with a preliminary event on the 24th of April 2024, the CYI Mixer, which was dedicated to young researchers and organized by the Czech Young Immunologists (CYI). It offered a BD cytometry workshop, scientific lectures, networking activities, and a panel discussion concerning bridging the lab to market.



The program continued the 25th of April 2024 when the official day of immunology was celebrated with morning lectures given by the researchers who received the CIS “Sterzl’s Award” and CIS-ARPA “Pospisil-Campa-Mosca Award” for the best scientific publications at the end of last year. In the afternoon, the series of lectures was completed by a lecture given by an invited keynote speaker Prof. Adriana Albini (European Institute of Oncology, Milan, Italy), one of the most internationally recognized researchers. The day was concluded by a piano concert of Lucia Biľová and Dana Miklošová.

All activities were under the auspices of the European Federation of Immunological Societies (EFIS). The participation of Prof. Albini was in collaboration with the Italian Ambassy and the Italian Institute of Culture in the frame of the Day of Italian Research and Made in Italy in the World. The full program was streamed online to allow more extended participation.



On the International Day of Immunology itself, the 29th of April 2024, Prof. Pramod Srivastava, Director of Center for Immunotherapy of Cancer and Infectious Diseases and a master in the study of stress-induced proteins in immune response to cancer, discovering heat shock protein cross presentation of antigens, visited the Laboratory of Immunotherapy at the IMIC. By long lasting friendship with the head of the Laboratory, Dr. Luca Vannucci, he spent a day in the company of the laboratory members. Together they discussed their research activities as well as results, also in the view of possible collaborations for the advancement of anticancer immunotherapies.